Replimune Group, Inc. (REPL)
| Market Cap | 768.33M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -213.02M |
| Shares Out | 68.42M |
| EPS (ttm) | -3.20 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 531,852 |
| Open | 10.93 |
| Previous Close | 10.95 |
| Day's Range | 10.77 - 11.29 |
| 52-Week Range | 4.92 - 12.97 |
| Beta | 1.19 |
| Analysts | Strong Buy |
| Price Target | 17.00 (+51.38%) |
| Earnings Date | Nov 12, 2024 |
About REPL
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company’s proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors. The company is also developing RP2, which is in Phase I clinical t... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for REPL stock is "Strong Buy." The 12-month stock price forecast is $17.0, which is an increase of 51.38% from the latest price.
News
Replimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024)
Oral presentation highlighting IGNYTE primary analysis data shows anti-tumor activity across all subgroups with injected and non-injected lesions responding with similar frequency, depth, duration, an...
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WOBURN, Mass., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today annou...
Replimune to Present at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Late-breaking abstract featuring IGNYTE clinical trial data, including subgroup and initial biomarker analyses, selected for oral presentation
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WOBURN, Mass., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today annou...
Replimune Presents Primary Analysis Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at European Society for Medical Oncology (ESMO) Congress 2024
Data from the IGNYTE primary analysis shows clinically meaningful activity across all subgroups, including those who had received prior anti-PD1 and anti-CTLA-4 or had primary resistance to anti-PD1
Replimune: Strong Data In A Highly Differentiated Space
Replimune's RP1, an oncolytic immuno-gene therapy, shows promise with a 31.4% ORR in phase 2 trials for post PD-1 melanoma and non-melanoma skin cancers. RP2, adding an anti-CTLA-4 component to RP1, d...
Replimune Announces First Patient Dosed in IGNYTE-3 Clinical Trial in Advanced Melanoma
Confirmatory Phase 3 Trial to assess efficacy and safety of the investigational oncolytic immunotherapy, RP1 (vusolimogene oderparepvec) in combination with nivolumab in patients with advanced melanom...
Replimune to Present at Two Upcoming Investor Conferences
WOBURN, Mass., July 30, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, ...
Replimune to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
WOBURN, Mass., June 07, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, ...
Replimune Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma
Primary endpoint data shows 12-month overall response rate (ORR) of 33.6% Biologics license application (BLA) submission intended for 2H 2024; first patient expected to be enrolled in IGNYTE-3 confirm...
Replimune Presents Positive Data from RP1 and RP2 Clinical Programs at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
-- Investigator-assessed 12-month results from the IGNYTE clinical trial of RP1 plus nivolumab in anti-PD-1 failed melanoma demonstrate an overall response rate of 32.7% and duration of response consi...
Replimune to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
WOBURN, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies...
Replimune Reports Fiscal Fourth Quarter and Year Ended 2024 Financial Results and Provides Corporate Update
WOBURN, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, t...
Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research (AACR) 2024 Annual Meeting
RP1 monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent and complete response rate of nearly 22 percent in evaluable patients RP1 monotherapy showed clear a...
Replimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitions
Philip Astley-Sparke to transition from current role of CEO to Executive Chairman Planned leadership changes position the Company for commercialization Preparations on track to submit RP1 biologics li...
Replimune Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update
WOBURN, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, ...
Replimune to Present at the 42nd Annual J.P. Morgan Healthcare Conference
WOBURN, Mass., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, ...
Replimune shares plunge as skin cancer therapy fails to meet primary clinical-trial goals
Replimune Group Inc. shares REPL, +5.21% dropped more than 40% premarket on Tuesday after the biotech company said an investigational cancer therapy had failed to meet its primary goals in a clinical ...
Replimune Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failed Melanoma and Non-Melanoma Skin Cancers
RP1 in combination with cemiplimab demonstrated clinically meaningful improvements in complete response rate and duration of response compared to cemiplimab in the CERPASS clinical trial, but did not ...
Replimune Presents Updated Data on RP2 in Uveal Melanoma during Plenary Session at the 20th International Congress of the Society for Melanoma Research
RP2 as monotherapy and in combination with nivolumab showed a favorable safety profile and durable responses in nearly 30 percent of patients, all with previously treated disease RP2 as monotherapy an...
Replimune Reports Fiscal Second Quarter 2024 Financial Results and Provides Corporate Update
The Company plans to hold a conference call in early December to provide a comprehensive RP1 skin cancer program update including:
Replimune Presents Updated Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers During Oral Presentation at the 38th Annual Meeting of the Society for Immunotherap
RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable patients RP1 as monotherapy showed clear anti-tumor activity with an overall respons...
Tessellate BIO Emerges from Stealth
The company aims to become a global leader in precision oncology by redefining Synthetic Lethality to treat large, currently unserved patient populations Lead program targets Alternative Lengthening o...
Replimune: Q4 2023 Data Readouts Of RP1 Makes This A Must Watch
Replimune Group, Inc. results from the registration-directed phase 2 CERPASS trial, using RP1 + Libtayo for the treatment of patients with cutaneous squamous cell carcinoma, are expected Q4 of 2023. T...
Replimune Reports Fiscal First Quarter 2024 Financial Results and Provides Corporate Update
Topline data from the registration-directed CERPASS clinical trial of RP1 combined with Libtayo ® (cemiplimab-rwlc) in cutaneous squamous cell carcinoma expected in early Q4 2023 and Biologics License...